Spatial multi-omics profiling mapped shifting macrophage populations across MASLD progression and identified markers that could support patient stratification for clinical trials. The study describes how tissue-level immune heterogeneity changes over disease stages, providing candidate biomarker signals tied to macrophage composition. For trial design, macrophage-associated markers can be used to enrich for likely responders or to stratify endpoints by underlying biology. The report specifically points to spatial multi-omics as the method enabling detection of location-linked cellular states. The work frames the macrophage changes as actionable for future trial selection and biomarker development in MASLD, a growing therapeutic focus area.